phase 1_completion
saveAkeso Inc — ebronucimab (Phase I Trial Completion)
community read0 votes
Therapy area: Metabolic Disorders. Indication: Heterozygous Familial Hypercholesterolemia (heFH), Hypercholesterolemia, Mixed Dyslipidemia
Therapy area: Metabolic Disorders. Indication: Heterozygous Familial Hypercholesterolemia (heFH), Hypercholesterolemia, Mixed Dyslipidemia